Pfizer: erinevus redaktsioonide vahel
Eemaldatud sisu Lisatud sisu
P liigendus, {{IPA|... |
PResümee puudub |
||
13. rida: | 13. rida: | ||
| tooted = |
| tooted = |
||
| teenused = |
| teenused = |
||
| käive = {{decrease}} 51,75 <abbr title="miljard">mld</abbr> [[Ameerika Ühendriikide dollar|$]] <small>(2019)</small><ref name="pfizerFR2019" /> |
|||
| käive = |
|||
| tegevuskasum = {{increase}} 16,30 mld $ <small>(2019)</small><ref name="pfizerFR2019" /> |
|||
| tegevuskasum = |
|||
| puhaskasum = {{increase}} 16,27 mld $ <small>(2019)</small><ref name="pfizerFR2019" /> |
|||
| puhaskasum = |
|||
| vara = assets = {{increase}} 167,489 mld $ <small>(2019)</small><ref name="pfizerFR2019" /> |
|||
| vara = |
|||
| omakapital = {{decrease}} 63,14 mld $ <small>(2019)</small><ref name="pfizerFR2019" /> |
|||
| omakapital = |
|||
| omanik = <!-- või | omanikud = --> |
| omanik = <!-- või | omanikud = --> |
||
| töötajaid = u 88 300 <small>(2019)</small> |
| töötajaid = u 88 300 <small>(2019)</small> |
||
35. rida: | 35. rida: | ||
==Viited== |
==Viited== |
||
{{viited|allikad= |
{{viited|allikad= |
||
<ref name="pfizerFR2019">{{cite web|url=https://s21.q4cdn.com/317678438/files/doc_financials/2018/ar/Pfizer-2019-Financial-Report.pdf|title=Financial Review - Pfizer Inc. and Subsidiary Companies|access-date=17. märtsil 2020|year=2019|publisher=Pfizer}}</ref> |
|||
<ref name=Longman>{{citation|last=Wells|first=John C.|year=2008|title=Longman Pronunciation Dictionary|edition=3rd|publisher=Longman|isbn=9781405881180}}</ref> |
<ref name=Longman>{{citation|last=Wells|first=John C.|year=2008|title=Longman Pronunciation Dictionary|edition=3rd|publisher=Longman|isbn=9781405881180}}</ref> |
||
<ref name=AP>{{cite web|url=https://apnews.com/article/pfizer-vaccine-effective-early-data-4f4ae2e3bad122d17742be22a2240ae8 |title=Pfizer says COVID-19 vaccine is looking 90% effective |trans-title= |publisher=[[Associated Press|AP News]] |date=9. november 2020, 19:00 |access-date=9.11.2020 |website=apnews.com |language=en |author1=Linda A. Johnson|author2=Lauran Neergaard|quote=“We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.”}}</ref> |
<ref name=AP>{{cite web|url=https://apnews.com/article/pfizer-vaccine-effective-early-data-4f4ae2e3bad122d17742be22a2240ae8 |title=Pfizer says COVID-19 vaccine is looking 90% effective |trans-title= |publisher=[[Associated Press|AP News]] |date=9. november 2020, 19:00 |access-date=9.11.2020 |website=apnews.com |language=en |author1=Linda A. Johnson|author2=Lauran Neergaard|quote=“We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.”}}</ref> |
Redaktsioon: 9. november 2020, kell 22:00
Pfizer Inc. | |
---|---|
Tüüp | börsiettevõte |
Asutatud | 1849 |
Asutajad |
Charles Pfizer Charles F. Erhart |
Peakorter | New York |
Tegevuspiirkond | kogu maailm |
Käive | 51,75 mld $ (2019)[1] |
Tegevuskasum | 16,30 mld $ (2019)[1] |
Puhaskasum | 16,27 mld $ (2019)[1] |
Vara | assets = 167,489 mld $ (2019)[1] |
Omakapital | 63,14 mld $ (2019)[1] |
Töötajaid | u 88 300 (2019) |
Koduleht | pfizer.com |
Pfizer Inc. (ˈfaɪzər)[2] on Ameerika Ühendriikides asuv ravimifirma peakorteriga New Yorgis.
Artikli kirjutamine on selles kohas pooleli jäänud. Jätkamine on kõigile lahkesti lubatud. |
2020. aasta 9. novembril teatas ettevõtte esindaja dr Bill Gruber saavutustest koroonavaktsiini väljatöötamisel.[3]
Viited
- ↑ 1,0 1,1 1,2 1,3 1,4 "Financial Review - Pfizer Inc. and Subsidiary Companies" (PDF). Pfizer. 2019. Vaadatud 17. märtsil 2020.
- ↑ Wells, John C. (2008), Longman Pronunciation Dictionary (3rd ed.), Longman, ISBN 9781405881180
- ↑ Linda A. Johnson; Lauran Neergaard (9. november 2020, 19:00). "Pfizer says COVID-19 vaccine is looking 90% effective". apnews.com (inglise). AP News. Vaadatud 9.11.2020.
“We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.”
Välislingid
- Sarah Boseley ja Philip Oltermann, Covid-19 vaccine candidate is 90% effective, says Pfizer, TheGuardian.com, 9. november 2020